Glycominds, which develops a unique technology and provides via it CLIA certified clinical laboratory groundbreaking services for early detection and management of Multiple Sclerosis (MS), reported that it has received approval from the Japanese Patent Office for the registration of its application for a patent for its main process for early diagnosis and management of MS.
The approval of this Patent further strengthens the intellectual property of Glycominds and is an expansion of the extensive patent protection held by the company, which has more than 100 issued and registered patents. Glycominds now intends to examine possible entry into the Japanese market, which is considered the second largest market in the medical field....... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1092